Ponezumab

Drug Profile

Ponezumab

Alternative Names: Anti-human Aβ28-40 IgG1; Antibody 2286; PF-04360365; PF-4,360,365; RN 1219

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Rinat Neuroscience
  • Developer Pfizer
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Cerebral amyloid angiopathy

Most Recent Events

  • 04 May 2016 Discontinued - Phase-II for Cerebral amyloid angiopathy in USA, United Kingdom, Canada, France, Netherlands (IV) (Pfizer pipeline, May 2016)
  • 01 Sep 2015 Pfizer completes a phase II trial in Cerebral amyloid angiopathy in USA, Canada, France, Netherlands and United Kingdom (IV) (NCT01821118)
  • 07 Nov 2014 Phase-II clinical trials in Cerebral amyloid angiopathy in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top